动态18F-FMISO PET/CT肿瘤控制概率模型的前瞻性验证:头颈癌放疗
前瞻性纳入25例头颈癌患者,放疗前行动态18F-FMISO PET/CT,验证基于MFMISO的肿瘤控制概率模型。MFMISO是唯一在独立验证队列中确认的预后参数(一致性指数0.71,P=0.004),支持动态18F-FMISO用于患者分层和缺氧指导的放疗个体化。
要点
- 动态18F-FMISO PET/CT的MFMISO参数可前瞻性验证肿瘤控制概率模型。
- MFMISO是唯一在验证队列中确认的预后参数(一致性指数0.71,P=0.004)。
- TMRmax、GTV、相对缺氧体积及GTV联合TMRmax均未能按结局分层。
核心结论
- 本研究前瞻性验证了MFMISO与复发风险的关系。
- 数据支持进一步评估和外部验证动态18F-FMISO PET/CT作为患者分层和缺氧指导放疗个体化(包括剂量绘画)的有前景方法。
研究设计与样本
- 前瞻性队列研究,纳入25例头颈癌患者,放疗前行动态18F-FMISO PET/CT(注射后0-240分钟)。
- 评估18F-FMISO影像参数,包括基于药代动力学建模的缺氧指标MFMISO、注射后4小时最大肿瘤/肌肉比值(TMRmax)、大体肿瘤体积(GTV)、基于MFMISO的相对缺氧体积及GTV联合TMRmax的logistic回归模型。
- 与既往训练队列(n=15)比较,使用训练队列确定的一致性指数(单因素Cox回归)和Kaplan-Meier分析(含log-rank检验)验证各参数对局部控制的预后价值。
主要发现
- 肿瘤控制概率模型得到确认,动态18F-FMISO可依据放疗结局将患者分层为不同风险组。
- MFMISO是唯一在独立验证队列中确认的预后参数(一致性指数0.71;P=0.004)。
- 其他参数如TMRmax、GTV、相对缺氧体积及GTV联合TMRmax均未能按结局分层患者组(P=无统计学意义)。
关键数值与推荐
- MFMISO在独立验证队列中的一致性指数为0.71,P=0.004。
- 其他参数(TMRmax、GTV、相对缺氧体积、GTV联合TMRmax)在验证队列中P值无统计学意义。
临床怎么用
- 动态18F-FMISO PET/CT的MFMISO可用于头颈癌放疗前患者风险分层。
- 该影像参数有望支持缺氧指导的放疗个体化,包括剂量绘画,但需进一步外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our purpose was to evaluate an imaging parameter-response relationship between the extent of tumor hypoxia quantified by dynamic 18F-fluoromisonidazole (18F-FMISO) PET/CT and the risk of relapse after radiotherapy in patients with head and neck cancer. Methods: Before a prospective cohort of 25 head and neck cancer patients started radiotherapy, they were examined with dynamic 18F-FMISO PET/CT 0-240 min after tracer injection. 18F-FMISO image parameters, including a hypoxia metric, MFMISO, derived from pharmacokinetic modeling of dynamic 18F-FMISO and maximum tumor-to-muscle ratio (TMRmax) at 4 h after injection, gross tumor volume (GTV), relative hypoxic volume based on MFMISO, and a logistic regression model combining GTV and TMRmax, were assessed and compared with a previous training cohort (n = 15). Dynamic 18F-FMISO was used to validate a tumor control probability model based on MFMISO The prognostic potential with respect to local control of all potential parameters was validated using the concordance index for univariate Cox regression models determined from the training cohort, in addition to Kaplan-Meier analysis including the log-rank test. Results: The tumor control probability model was confirmed, indicating that dynamic 18F-FMISO allows stratification of patients into different risk groups according to radiotherapy outcome. In this study, MFMISO was the only parameter that was confirmed as prognostic in the independent validation cohort (concordance index, 0.71; P = 0.004). All other investigated parameters, such as TMRmax, GTV, relative hypoxic volume, and the combination of GTV and TMRmax, were not able to stratify patient groups according to outcome in this validation cohort (P = not statistically significant). Conclusion: In this study, the relationship between MFMISO and the risk of relapse was prospectively validated. The data support further evaluation and external validation of dynamic 18F-FMISO PET/CT as a promising method for patient stratification and hypoxia-based radiotherapy personalization, including dose painting.
引用
- Thorwarth D, Welz S, Mönnich D, et al. Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic 18F-FMISO PET for Head and Neck Cancer Radiotherapy. J Nucl Med. 2019. PMID: 31076504. doi:10.2967/jnumed.119.227744
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。